Education
About Us
Working with TipRanks
Follow Us
Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Apr-1051
Advanced Solid Tumor
Phase I
Recruiting
Study of APR-1051 in Patients With Advanced Solid Tumors
Jan 18, 2024
―
Atrn-119
Advanced Solid Tumor
Phase I/II
Recruiting
Study Of ATRN-119 In Patients With Advanced Solid Tumors
May 17, 2021
―
Apr-548 + Azacitidine
Myelodysplastic Syndromes, Mds
Phase I
Terminated
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Nov 13, 2020
―
Apr-246 (Eprenetapopt) + Acalabrutinib In Cll, Apr-246 (Eprenetapopt) 4.5 G/D + Venetoclax + Rituximab In Cll, Apr-246 (Eprenetapopt) 4.5 G/D + (Acalabrutinib, Or, (Venetoclax +Rituximab)), In Cll And/Or Mcl And/Or Rt, Apr-246 (Eprenetapopt) 4.5 G/D + Venetoclax + Rituximab In Rt
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Phase I/II
Terminated
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Jun 01, 2020
―
Apr-246 (Eprenetapopt) + Pembrolizumab
Bladder Cancer, Urothelial Carcinoma, Advanced Solid Tumor, Non Small Cell Lung Cancer, Gastric Cancer, Nsclc
Phase I/II
Completed
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
May 07, 2020
―
Azacitidine, Venetoclax, Apr-246
Myeloid Malignancy
Phase I
Completed
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Dec 12, 2019
―
Apr-246
Acute Myeloid Leukemia Or Myelodysplastic Syndromes
Phase II
Completed
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Apr 26, 2019
―
Azacitidine, Apr-246 + Azacitidine
Mds
Phase III
Completed
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Nov 14, 2018
―
Apr-246, Pegylated Liposomal Doxorubicin Hydrochloride (Pld)
High-Grade Serous Ovarian Cancer
Phase II
Completed
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Aug 24, 2017
―
Apr-246, Carboplatin And Pegylated Liposomal Doxorubicin Hydrochloride (Pld)
Platinum Sensitive Recurrent High-Grade Serous Ovarian Cancer With Mutated P53
Phase I/II
Completed
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Mar 19, 2014
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Aprea Therapeutics Inc (APRE) have in its pipeline
APRE is currently developing the following drugs: Apr-1051, Atrn-119, Apr-548 + Azacitidine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.